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Vps34 is the primordial member of the PI3 kinase family involved in vesicular trafficking, nutrient signaling,
and autophagy. A report in Science unveils the Vps34 structure, providing new insights into the catalytic
mechanism, explainingwhy Vsp34 is so difficult to inhibit, and facilitating design of chemical tools and poten-
tial drugs.The oldest members of the family are not
always the easiest to understand and
manage. So it is with the phosphatidylino-
sitide 3-kinase (PI3K) brood. In an exciting
new paper, Roger Williams and col-
leagues have provided us with the first
molecular comprehension of the behavior
of the relatively poorly understood ances-
tral enzyme, Vps34 (vacuolar protein sort-
ing 34), encouraging hope that its activity
may be controlled pharmacologically. The
studies shed new light on how the whole
PI3K dynasty operates and on the interfa-
milial differences between the members
(Miller et al., 2010). There are significant
implications for understanding and treat-
ing cancer.
PI3Ks are important lipid kinases
that catalyze phosphorylation of the
30-hydroxy position of the inositol ring of
phosphatidylinositides, generating prod-
ucts that act as second messengers in
the cell. These lipid kinases are grouped
into three main classes (Vanhaesebroeck
et al., 2001). The class I PI3Ks— com-
prising the class IA catalytic isoforms
p110a, p110b, and p110d and the class
1Bmemberp110g—are themost studied.
Indeed, the p110a isoform is one of the
most frequently mutated kinases in
human malignancies (www.sanger.ac.uk/
genetics/CGP/cosmic/). p110a and the
other class I siblings, as well as the more
distant class IV PI3K-related protein
kinase relatives or PIKKs (including
mTOR), are being actively pursued as
cancer therapeutic targets, with drugs
now in the clinic (Workman et al., 2010).
In contrast, the sole class III ancestral iso-
form Vps34 and the class II isoforms are
much less understood and not so stronglylinked to oncogenesis (see Backer, 2008).
Moreover, whereas the crystal structures
of the a, d, and g isoforms have been
solved (Walker et al., 1999; Huang et al.,
2007; Berndt et al., 2010), facilitating the
design of potent and selective inhibitors,
this had been lacking for Vps34 before
the report by Miller et al.
The gene encoding Vps34 was first
cloned by Herm and Emr in 1990 following
a Saccharomyces cerevisiae screen that
revealed its involvement in vesicular traf-
ficking (Backer, 2008). It is expressed
ubiquitously in all eukaryotes. Vps34 was
subsequently demonstrated to be the pri-
mordial PI3 kinase with a particular sub-
strate and product profile, converting
phophatidylinositol (PI) to phosphatidyli-
nositol-3-phosphate (PI3P). The PI3P pro-
duct in turn recruits proteins containing
FYVE or PX domains, thereby initiating
various complexes at the membranes of
endosomes, phagosomes and autopha-
gosomes (Backer, 2008). Autophagy is
the critical catabolic lysosomal/vacuolar
self-digestion pathway that is activated
by nutrient deprivation and other stresses
and controls the balance of damage
mitigation versus survival promotion
(White and DiPaola, 2009). There appears
to be a core autophagy-regulating com-
plex containing: (1) Vps34 itself; (2) the
N-terminally myristoylated putative ki-
nase Vps15, which stimulates the PI3K
activity of Vps34 at membranes; and (3)
Beclin 1, which shows allelic loss in some
cancers. Recruitment of ATg14L to this
core complex is thought to promote in-
duction of the first stages of autophagy,
whereas the alternative binding of UVRAG
and/or Rubicon to the Beclin 1/Vps34Cancer Celcomplex controls the later stages of
autophagosome maturation (Funderbunk
et al., 2010). Thus, it is clear that the
orchestration of the Vps34 PI3K activity
by its associating protein partners lies at
the heart of the autophagic process (Fig-
ure 1A). In addition to vesicular trafficking,
Vps34 has been implicated in nutrient
sensing and protein synthesis through
the mTOR pathway and in signal trans-
duction downstream of G protein-cou-
pled receptors (Backer, 2008). However,
there are many outstanding questions
about the cellular roles of Vps34 under
homeostatic and pathological conditions,
including cancer, which structural biology
and improved chemical probes—used
alongside genetic methods—could help
us to answer.
This is where Miller et al. rode to the
rescue. First, they solved the crystal
structure of Vps34 from Drosophila mela-
nogaster at 2.9A˚ resolution, revealing
several important insights. A striking dif-
ference with the class I PI3Ks is the fully
ordered activation loop in Vps34. This
loop controls phosphoinositide substrate
preferences and is disordered in class I
PI3K structures (Figure 1B), The under-
standing of this part of the Vps34 structure
allowedadetailedproposal for its catalytic
mechanism, supported by mutagenesis
of key residues. Comparison of Vps34
with p110g structures showed that the
catalytic loop of Vps34 is possibly cap-
tured in an active conformation, whereas
p110g structures could correspond to an
inactive conformation (Walker et al., 1999).
The difference between the two suggests
a transition from inactive to active forms
thatmay represent a fascinating activationl 17, May 18, 2010 ª2010 Elsevier Inc. 421
Figure 1. Structure, Function, and Inhibition of Vps34
(A) Schematic of Vps34 in complex with Beclin 1, Atg14L, and Vps15. Vps15 anchors this multiprotein complex to the membrane via its N-terminally attached
myristoyl group (purple) and activates the essential PI3K activity of Vps34. The Vps34 substrate, phosphatidylinositol (PI), and its product, phosphatidylinositol-
3-phosphate (PI3P), are shown in red. The complex with ATg14L is involved in the induction of the first stages of autophagosome formation, whereas
alternative complexes with UVRAG and/or Rubicon (not shown, see text) are involved in the later stages of autophagosome maturation.
(B) An overlay of p110g (PDB code 3 dbs) shown in blue and Vps34 (PDB code 2x6h) shown in orange with the P loop that binds the phosphates of ATP in pink and
red, respectively, the hinge in green/light green, the activation loop in yellow/lemon, and the catalytic loop in purple/light purple. Also indicated are helices ka1
and ka2 and the loop connecting them. Important structural differences with p110g include a shift in the P loop in Vps34, the lack of a bulge in the hinge region in
Vps34, the different conformation of the catalytic loop and the ordering of the activation loop.
(C) The binding of the fragment-like 3-methyladenine (3-MA) in Vps34 (PDB code 2x6f). 3-MA is shown with carbon atoms in red and a solvent accessible surface
superimposed. The two hydrogen bond interactions with the hinge are indicated as dashed lines. The hydrophobic residues that snugly surround 3-MA and
appear to be important for its specificity against Vps34 are labeled.
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all PI3Ks.
Of particular importance for the action
of PI3K inhibitors is the smaller ATP-
binding pocket in Vps34 (volume 800 A˚3)
compared to that of the class I p110g
(volume 1200 A˚3). This is caused by an
inward curling of the loop that binds the
phosphates of ATP (P loop), together
with a similar shift in the loop connecting
the so-called ka1/ka2 helices (Figure 1B).
In addition, the one residue shorter hinge
region between the N and C lobes of the
kinase domain of Vps34 results in the
absence of the bulged-out space in this
region that is common to class I PI3Ks. It
is clear that the smaller ATP cavity of422 Cancer Cell 17, May 18, 2010 ª2010 ElsVps34 restricts the binding of typical
PI3K inhibitors, which is consistent with
the weak affinities for Vps34 of the com-
monly used class I PI3K tool inhibitors
PIK-90 and PI-103. In addition, Miller
et al. argue that whereas some class I
PI3Ks, notably p110d (Berndt et al.,
2010), can form an induced allosteric
specificity pocket when binding pro-
peller-shaped inhibitors such as PIK-39,
this is prevented in the more rigid and
constrained ATP pocket of Vsp34.
Lacking a potent Vps34 inhibitor,
3-methyladenine (3-MA) has been used
at very high concentration (e.g., 10 mM)
in cells to inhibit this class III PI3K and
autophagy (Kondo et al., 2005). Millerevier Inc.et al. determined the structure of the
complex between Vps34 and 3-MA (Fig-
ure 1C), which has a very low molecular
weight and so fits well into the smaller
ATP pocket. Furthermore, although not
potent, 3-MA shows some selectivity
for Vps34 versus class I PI3Ks, which is
explained by the conserved hydrophobic
residues that snugly surround 3-MA in
Vps34.
Using these new structural insights,
Miller et al. were able to reverse the mod-
est selectivity of PIK-93 for p110g over
Vps34 (IC50 values 36 nM and 4 nM,
respectively) as a proof of concept for
structure-based design against Vps34.
They synthesized the analog PT210 that
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(450 nM) but 1000-fold less potent for
p110g (4,428nM) giving a 10-fold selec-
tivity in favor of Vps34. At this stage there
are no structural data confirming the
binding mode of PT210 in Vps34 or
p110g, but the results suggest that even
more potent and selective inhibitors may
be within reach.
So how might such emerging inhibitors
be used? First, they could be employed
as improved tools to ask outstanding
questions about the precise roles of
Vps34 in cells. With respect to therapy,
since autophagy is a double-edged sword
in cancer (White and DiPaola, 2009) the
jury is still out as to whether inhibiting
autophagy would be a good or a bad
thing. The potential therapeutic effects of
pharmacologic Vps34 modulation may
well be context-dependent, and thus
there could perhaps be a need for bio-
markers for patient selection. Improved
Vps34 inhibitors would allow us to deter-
mine in a better way than before whether
it is time for the newly unveiled ancestral
PI3K to join some of the upstart younger
generation as a new cancer drug target.Furthermore, the recent emergence of
GOLPH3 as an oncoprotein involved in
vesicular trafficking (Scott and Chin,
2010) suggests that this area might be of
broader therapeutic significance, giving
rise to an even more extended target
family.
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Mutations in BRCA1 predispose to tumorigenesis presumably from the inability to accurately repair DNA
double-strand breaks by homologous recombination. Two new papers shed light on how loss of the DNA
damage response protein 53BP1 reverses phenotypes of BRCA1mutant cells, with potential clinical implica-
tions.Defects in homologous recombination
(HR) cause chromosome instability and
are associated with tumor predisposition
(Moynahan and Jasin, 2010). The inability
to accurately repair DNA double-strand
breaks (DSBs) by HR ultimately forces
cells to rely on alternative nontemplate-
based repair pathways, including nonho-
mologous end joining (NHEJ), resultingin the accumulation of chromosome aber-
rations, a hallmark of tumor cells. BRCA1,
mutations of which are associated with
a markedly increased risk of breast and
ovarian cancer, was the first tumor sup-
pressor gene identified to have an impor-
tant role in HR.
Recently, a surprising observation was
reported for mice deficient in BRCA1and the DNA damage response protein
53BP1, in that loss of 53BP1 rescued
the embryonic lethality, tumor suscepti-
bility, and premature aging of mice homo-
zygous forBrca1 exon 11 deletion without
fully eliminating the chromosome insta-
bility (Cao et al., 2009). Although defi-
ciency of other DNA damage response
factors such as p53 and Chk2 hadl 17, May 18, 2010 ª2010 Elsevier Inc. 423
